Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of Adagrasib in Healthy Japanese Participants
NCT07723118Phase 1Completed
- Sponsor
- Mirati Therapeutics
- Start
- Aug 2026
- Primary completion
- Sep 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of adagrasib in non-small cell lung cancer (NSCLC), sponsored by Mirati Therapeutics. Primary endpoints: Maximum Observed Plasma Concentration, Time of Maximum Observed Plasma Concentration and 5 more. Started Aug 2026; status: completed.
02
Drugs
adagrasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07723118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07723118.